மைக் ஃபார்பர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Mountain Valley MD Holdings Inc says its Quicksome technology could change vaccine landscape latest cold chain tests
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Emerging Biotech Company MVMD Looks To Take On Cancer, COVID-19 And More
ibtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.com Daily Mail and Mail on Sunday newspapers.
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
KULR Technology Group Inc (OTCQB:KULR) posted first-quarter results that saw its revenue jump 439% year-over-year on the back of new orders for products and engineering services from military and aerospace customers. For the period ended March 31, 2021, the San Diego, California-based company reported revenue of $417,905, compared to $77,500 in the first quarter of 2020. The company chalked up the bump in revenue to “new orders received for products and engineering services for military and aerospace customers.” “The company continues to build its relationships with a wide range of energy, transport and aerospace partners and actively served 13 customers in the quarter,” said KULR.
Mountain Valley MD says it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials
The company said the cancer patent has been filed for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens Mountain Valley MD said it believes the research will have near-immediate application to direct human trials based on safety and efficacy of ivermectin
Mountain Valley MD Holdings Inc. (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ -
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Summary
MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
The Company is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma.
vimarsana © 2020. All Rights Reserved.